Given their pivotal roles in cancer cell biology, phospholipids present potential targets for therapeutic intervention. Inhibitors targeting enzymes involved in phospholipid metabolism, such as phospholipase A2 or PI3K, have shown promise in preclinical studies. Additionally, phospholipid-based drug delivery systems, such as liposomes, can improve the delivery and efficacy of chemotherapeutic agents.
